Summary

Patients with type 2 diabetes are at greater risk for cardiovascular events, and thiazolidinediones, approved for the management of type 2 diabetes, have demonstrated an atheroprotective effect in animal models of atheroscleroisis. The CHICAGO study sought to further elucidate the potential protective effect of the thiazolidinedione pioglitazone in patients with type 2 diabetes.